VIP regulates IL-10 expression in regulatory B cells, offering a potential new therapeutic strategy for ulcerative colitis by modulating gut immune responses.
Neuro-immune axisVIP connects the enteric nervous system to immune regulation through regulatory B cell IL-10 production
What the researchers found
VIP regulates IL-10 expression in regulatory B cells, influencing the Th1/Th2 balance and potentially providing a new mechanism for treating ulcerative colitis.
Why it matters
Ulcerative colitis has increasing global incidence with limited treatment options. VIP's ability to modulate gut immunity through regulatory B cells could lead to novel, targeted therapies.
The numbers in context
Proposed pathway: VIP → Bregs → IL-10 → Th2 shift; Bregs produce IL-10, IL-35, TGF-β
How the study worked
Narrative review of published literature on VIP immunomodulation and regulatory B cell biology in colitis.
Who was studied
Review article (no study population)
What this study cannot tell us
Review of an evolving field. The exact mechanisms of VIP-Breg-IL-10 interaction are still being clarified.
How to read the evidence
Review article synthesizing animal and human experimental data. Promising mechanistic basis but clinical application remains theoretical.
When this study was published
Published in 2020. VIP-based immunomodulation for IBD continues to be researched.
The bigger picture
Understanding the neuro-immune axis in the gut — how neuropeptides like VIP influence immune cells — could unlock new treatment approaches for inflammatory bowel disease.
Questions still open
- Could exogenous VIP administration treat UC in clinical trials?
- What is the optimal route for delivering VIP to the gut?
- Are VIP levels altered in UC patients compared to healthy individuals?
Common questions
What is VIP and what does it do in the gut?
How could VIP help treat ulcerative colitis?
Read the original research
Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells.
World journal of gastroenterology, 26(48), 7593-7602
Citation
Sun, Xiong; Huang, Yao; Zhang, Ya-Li; Qiao, Dan; Dai, Yan-Cheng. (2020). Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells.. World journal of gastroenterology, 26(48), 7593-7602. https://doi.org/10.3748/wjg.v26.i48.7593